immunoSEQ Blog

AACR Insight: A new age of theranostics – Transforming the immuno-oncology landscape

SB_Pic

From Sharon Benzeno, PhD, MBA, Sr. Director, New Product Development At the 2015 American Association of Cancer Research (AACR) annual conference in Philadelphia, April 18-22, plenary sessions, posters and abstracts were again abuzz with the ability of monotherapy and combination drugs to amplify and expand T cell responses and ultimately kill cancer cells. From standard of… Read More→

Categorized in: From our Employees |

Adaptive Customers Publish Latest Results in Science Express Journal

A couple of weeks ago, a team of researchers from Washington University, University of Oklahoma, and EMD Millipore Corporation published results from a study in which they used the immunoSEQ assay to determine if a dendritic cell vaccine increased naturally occurring new HLA class I-restricted neoantigens in patients with advanced melanoma.  The overall conclusion is… Read More→

Categorized in: Announcements |

Adaptive Biotechnologies and Researchers from MD Anderson Cancer Center Demonstrate Ability to Detect Hodgkin’s Lymphoma in Blood

SEATTLE, WA April 28, 2015 – Adaptive Biotechnologies today announced the recent publication of a study conducted with researchers at The University of Texas MD Anderson Cancer Center showing that the company’s next-generation sequencing-based approach to identification and quantification of populations of B cells can detect tumor-specific DNA sequences in the blood of people with… Read More→

Categorized in: Press Release |

Adaptive Customer Publish Latest Results in Blood (online)

A couple of weeks ago, a team of researchers from Emory University, Fred Hutchinson Cancer Research Center, Adaptive Biotechnologies, University of Minnesota, and Seattle Children’s Research Institute published results from a study in which they used the immunoSEQ assay to study the effects of CMV reactivations in post-transplant CD8 reconstitution and exhaustively evaluate the underlying TCRβ immune repertoire. … Read More→

Categorized in: Announcements |

Adaptive Biotechnologies’ clonoSEQ Minimal Residual Disease Test Detects Relapse with Higher Specificity than PET/CT in Diffuse Large B-cell Lymphoma Patients

SEATTLE, WA April 22, 2015 – Adaptive Biotechnologies today announced the recent publication of a study demonstrating that analysis of circulating tumor DNA (ctDNA) using the company’s next-generation sequencing-based minimal residual disease  detection and quantification method (clinically-available as the clonoSEQtm MRD test) can detect relapse in diffuse large B-cell lymphoma (DLBCL) patients with significantly higher… Read More→

Categorized in: Press Release |

Adaptive Customers Publish Latest Results in Blood (online)

A couple of weeks ago, a team of researchers from Boston Children’s Hospital, Harvard Medical School, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, San Raffaele Scientific Institute, and Hospital for Sick Children published results from a study in which they used the immunoSEQ assay to study the immune responses of humanized mice lacking murine MHCII… Read More→

Categorized in: Announcements |

Adaptive Biotechnologies and Collaborators to Present 4 Studies Demonstrating Clinical Relevance of Immunosequencing in the Treatment of Solid Tumors at the 2015 American Association for Cancer Research Annual Meeting

Adaptive Biotechnologies and Collaborators to Present 4 Studies Demonstrating Clinical Relevance of Immunosequencing in the Treatment of Solid Tumors at the 2015 American Association for Cancer Research Annual Meeting Seattle, WA – Adaptive Biotechnologies, the company pioneering Next Generation Sequencing (NGS) applications for cancer immunology, and its collaborators will present data demonstrating how profiling a… Read More→

Categorized in: Announcements |

Adaptive Customers Publish Latest Results in Immunology

A couple of months ago, a team of researchers from Oregon Health & Science University, KwaZulu-Natal Research Institute, Massachusetts General Hospital, Johns Hopkins School of Medicine, and Ragon Institute published results from a study in which they used the immunoSEQ assay to define a phenotypic marker panel to identify bacterial-reactive MR1-restrictive MAIT cells and broadly characterize… Read More→

Categorized in: Announcements |

Adaptive announces Multiple Myeloma Research Foundation and University of Torino 5 year collaboration

  Multiple Myeloma Research Foundation, University of Torino and Adaptive Biotechnologies Work to Speed Novel Minimal Residual Disease Monitoring Technologies to Patients   NORWALK, Conn. & SEATTLE – April 14, 2015 – The Multiple Myeloma Research Foundation (MMRF), in collaboration with the University of Torino (UofT) and Adaptive Biotechnologies, today announced a collaboration to perform sequencing-based… Read More→

Categorized in: Announcements |

Updates to the immunoSEQ Analyzer

This week, our immunoSEQ Analyzer website was updated with some new feature and user experience improvements. This release contains features that are visible to customers as well as tool and infrastructure work. Two of the more popular customer-facing features are summarized below. This release also includes numerous interface improvement throughout the Analyzer. R-Connector makes it easy… Read More→

Categorized in: Announcements, Software Tips |